SUNSHINE BIOPHARMA INC

SBFMNASDAQ

🏆 #4072 by market capEarnings Nov 10US Equity

$1.23▲ $0.01 (+0.82%)

🌙 After hours$1.21▼ 1.63%Regular close · extended-hours price shown

1h—

24h▲ 0.8%

7d—

14d—

30d—

1y—

🏦Market Cap

$3M

Small Cap

📈Revenue Growth (YoY)

-2.0%

Declining

📊Gross Margin

33.0%

Moderate

💵FCF Margin

—

⚖️P/S Ratio

0.1x

Cheap

Otter Score

Fair

No chart data available for SBFM.

Trading Snapshot

Day Range: $1.22 – $1.25
52-Week Range: $1.10 – $24.30
Volume: $2.24B
Avg Volume: $2.37B
Shares Outstanding: 2.4M
Next Earnings: Sep 2, 2026

Fundamentals Snapshot

Annual Revenue: $36M
Last Q Revenue: $8M
P/E Ratio: —
P/S Ratio: 0.1x
EPS (TTM): $-9.28
Dividend Yield: —

Why Investors Own SBFM

✓High-growth profile — revenue up +5.5% YoY with expanding US Equity exposure.
✓Healthy economics — 51% gross margin and 28% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$36M▲ +1.7% YoY

Gross Margin (TTM)

50.5%▲ +2.8% YoY

Operating Income (TTM)

$11M▲ +1.7% YoY

Free Cash Flow (TTM)

$10M▲ +1.7% YoY

About SUNSHINE BIOPHARMA INC

Sunshine Biopharma, Inc. operates as a pharmaceutical entity and a provider of nutritional supplements, primarily dedicating its efforts to the research and development of novel anticancer therapies. A key pipeline candidate is Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin, designed to combat a broad spectrum of malignancies, including leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, and liver cancers. Notably, Adva-27a also demonstrates efficacy against multidrug-resistant cancer cells, encompassing pancreatic, breast, small-cell lung, and uterine sarcoma cells. The company is also progressing SBFM-PL4, a compound under development as an anti-coronavirus treatment. In addition to its drug development, Sunshine Biopharma markets a range of nutritional products, such as the Essential 9 tablet and the Essential Calcium-Vitamin D supplement, alongside other scientifically formulated dietary aids. A collaboration with the University of Georgia supports the ongoing advancement of SBFM-PL4 as an anti-coronavirus agent. The firm's headquarters are situated in Pointe-Claire, Canada.

🦦